OPPI renews strategy to focus on Atmanirbhar Bharat- reinforces commitment to improving health outcomes in India

Building on a long heritage of innovation, the association puts deeper emphasis on Honble Prime Ministers clarion call of Jai Vigyan, Jai Anusandhan Monday, March 27, 2023 Strengthening its efforts to meet the unmet medical needs in the country, the Organisation of Pharmaceutical Producers of India OPPI, an industry body representing the global research-based pharmaceutical industry in India, has renewed its strategy to focus on Atmanirbhar Bharat.

Building on a long heritage of innovation, the association puts deeper emphasis on Hon'ble Prime Minister's clarion call of Jai Vigyan, Jai Anusandhan Monday, March 27, 2023: Strengthening its efforts to meet the unmet medical needs in the country, the Organisation of Pharmaceutical Producers of India (OPPI), an industry body representing the global research-based pharmaceutical industry in India, has renewed its strategy to focus on Atmanirbhar Bharat. The global pharma companies have made contributions to decreasing India's disease burden, strengthening the country's healthcare ecosystem, and improving the quality of life of its citizens. OPPI's renewed strategy encapsulates the essence of its commitment to enabling a healthier India through innovative solutions. The pharmaceutical industry in India is currently valued at $50 billion and is moving at a rapid pace to achieve the goal of self-reliance. Given this, OPPI has put the focus on 'Bharat Ke Liye' and is increasing efforts to converge, collaborate, and co-create with the government and other industry stakeholders to achieve the dream of an Atmanirbhar Bharat. The renewed strategy aims to highlight the legacy of the global pharma industry in India, and reinforce its commitment to India over the years, now and in the future. It will underscore the significant contributions made by OPPI member companies in areas such as pharmaceutical research and development, upholding industry quality standards, manufacturing, supply chain, and patient centricity & care, among others. Mr Suresh Pattathil, President, OPPI and GM AbbVie India said, "The global pharmaceutical industry has been an essential part of India's healthcare system for decades, and OPPI members have been at the forefront of bringing innovative medicines to patients in India. With the new approach, we hope to showcase the positive impact of the pharma industry in India and build a more informed and collaborative healthcare ecosystem. As OPPI, we are converging, collaborating, and co-creating with the government and other stakeholders to foster a brighter future for India@100." OPPI will focus on 4 critical pillars- enabling access, driving innovation, supporting health systems, and committing strategic investments. Access and innovation have always been the two key driving factors for progress in healthcare. The OPPI members, which represent the global research-based pharmaceutical companies, look forward to not only bringing novel therapies to market but also exploring new and sophisticated approaches to enhancing access to patients. The members will continue their focus on bringing innovative solutions for unmet medical needs and R&D; all in an effort to improve the quality of care and access to healthcare. There will be a renewed focus on strengthening healthcare systems through stronger government collaborations and greater strategic investments to address the healthcare issues that are most pressing.

"Our member companies are dedicated to advancing scientific research and innovation, which is crucial for addressing the complex healthcare challenges facing India. We have and will continue to be there Bharat Ke Liye. Since pre-independence, we've partnered with India to eradicate many diseases, address many epidemics, and lessen the country's disease burden together. The COVID-19 pandemic has further highlighted the critical role of the pharma industry in ensuring public health and safety" said Mr Vivek Sehgal, Director General, OPPI.

(Disclaimer: The above content is a press release and PTI takes no editorial responsibility for the same.).

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)